Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

Circulating Tumor DNA for Monitoring Disease Status
dbrock
Post ASCO 2019 Lung Cancer Round Table Discussion - Circulating Tumor DNA for Monitoring Disease Status
Author
Howard (Jack) West, MD
Image

We are excited to share with you more videos from a recent series of discussions between Drs. Howard (Jack) West, MD, Associate Clinical Professor, Medical Oncology, Executive Director, Employer Services at City of Hope Comprehensive Cancer Center, and Founder, President and CEO Of GRACE, Charu Aggarwal, MD, MPH with the Perelman Center for Advanced Medicine, University of Pennsylvania, and Benjamin Levy MD, Clinical Director Of Medical Oncology, Assistant Professor Of Oncology at the Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital.

The doctors recently collaborated from their respective geographical locations to review top discussion points from Lung Cancer from ASCO 2019.  In this video, the doctors discuss their thoughts on circulating tumor DNA for monitoring disease status.
 
For more, please visit http://cancerGRACE.org/.  To join the conversation, visit https://cancergrace.org/forum.

 

 

Video Language

Next Previous link

Previous PostNext Post

Related Content

Online Community

An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components:

  1. The antibody, which serves as the “horse,” specifically targets a protein found on cancer...

Bispecifics, or bispecific antibodies, are advanced immunotherapy drugs engineered to have two binding sites, allowing them to latch onto two different targets simultaneously, like a cancer cell and a T-cell, effectively...

The prefix “oligo–” means few. Oligometastatic (at diagnosis) Oligoprogression (during treatment)

There will be a discussion, “Studies in Oligometastatic NSCLC: Current Data and Definitions,” which will focus on what we...

Radiation therapy is primarily a localized treatment, meaning it precisely targets a specific tumor or area of the body, unlike systemic treatments (like chemotherapy) that affect the whole body.

The...

Biomarkers are genetic mutations (like EGFR, ALK, KRAS, BRAF) or protein levels (like PD-L1) in tumor cells that help guide personalized treatment, especially NSCLC, directing patients to targeted therapies or immunotherapies...

Hi Stan!  So good to hear from you.  I'm sorry for the late response.  I too have been out of town with family and missed your post, probably because I was...

It is so good to hear from you!  And I am so happy to hear that your holidays have been good and that you are doing well.  It sounds like your...

Recent Comments

JOIN THE CONVERSATION
Biomarkers
By JanineT GRACE … on
Radiation Therapy
By JanineT GRACE … on
Oligometastatic vs Oligoprogression
By JanineT GRACE … on
Hi Stan!! and happiest of holidays!
By dbrock on